[Antibioprevention in reconstructive arterial surgery. A double-blind study]

Area of Science:

• Vascular Surgery
• Infectious Disease Prevention
• Pharmacology

Background:

• Established antibiotic prophylaxis for reconstructive vascular surgery relies on limited controlled trials.
• Evidence supporting routine antibiotic use in this surgical field requires further robust investigation.

Purpose of the Study:

• To compare the efficacy of cefazolin versus placebo in preventing surgical site infections.
• To evaluate the impact of antibiotic prophylaxis on infection rates, amputation, and mortality in reconstructive vascular surgery.

Main Methods:

• A double-blind, randomized study involving 179 patients undergoing reconstructive vascular surgery.
• Patients were categorized into aorto-iliac, infra-inguinal, and extra-anatomic bypass groups.
• Infection rates, systemic and local infections, amputations, and mortality were compared between cefazolin and placebo groups.

Main Results:

• The cefazolin group (93 patients) experienced a 13.97% infection rate, with 1 amputation and 1 death.
• The placebo group (86 patients) had a significantly higher infection rate of 30.23%, with 1 amputation and 1 death.
• Statistical analysis confirmed a significant benefit of cefazolin in reducing infection incidence (chi-square test).

Conclusions:

• Perioperative cefazolin administration significantly decreases infection rates in reconstructive vascular surgery.
• Short-term, high-dose perioperative antibiotic prophylaxis is the optimal strategy to minimize infection risk.
• This study supports the routine use of cefazolin for infection prevention in vascular reconstructive procedures.